Empagliflozin in Black Versus White Patients with Heart Failure: Analysis of EMPEROR-Pooled
Circulation. 2022; online ahead of print DOI: 10.1161/CIRCULATIONAHA.122.062644
While analyses from DAPA-HF and EMPEROR-Reduced demonstrated a consistent benefit of SGLT2i in Black patients, data were limited to HFrEF and included a small number of Black patients. In the current analysis, the efficacy and safety of empagliflozin according to Black vs White race in the Americas was assessed across the spectrum of EF in EMPEROR-Pooled, a combined dataset from both EMPEROR trials.
Across the 3,502 enrolled patients from the Americas, Black vs White patients were at higher risk of HF events. However, outcomes were improved with empagliflozin to a similar extent in Black and White patients when assessed irrespective of EF, with a suggestion of potential enhanced efficacy in Black vs White patients, particularly in HFrEF. The safety profile of empagliflozin was comparable in Black and White patients.
Keywords:
